Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|A||FC, ICC, IHC||M||HRP||Monoclonal Antibody|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||Maintain at 2-8°C in undiluted aliquots for up to 6 months. Avoid freezing after reconsituition.|
|Material Size||100 µg|
|MOUSE ANTI-BROMODEOXYURIDINE (BrdU) HRP CONJUGATED MONOCLONAL ANTIBODY - 2392251||2392251|
|MOUSE ANTI-BROMODEOXYURIDINE (BrdU) -2669953||2669953|
|MOUSE ANTI-BROMODEOXYURIDINE (BrdU) -2726744||2726744|
|Reference overview||Pub Med ID|
|S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment.|
Gonchoroff, N J, et al.
J. Immunol. Methods, 93: 97-101 (1986) 1986
We have previously described a monoclonal antibody (BU-1) to 5-bromo-2-deoxyuridine (BrdUrd) that is useful for measurement of cell cycle S-phase. BU-1 hybridoma supernatant reacted with incorporated BrdUrd after the cells had been ethanol fixed; without a requirement for acid or base denaturation. We have found that this reactivity is lost if purified antibody is used, if the culture supernatants are heated, or if a mycoplasma-free hybridoma line is isolated. The supernatant contained endogenous DNase activity that was a result of mycoplasma infection of the cell line. This DNase activity was required for staining the cells with BU-1 in the absence of other denaturation steps. The endogenous DNase could be substituted for by the addition of bovine pancreatic DNase I. The disruption of the double stranded DNA structure with an enzyme rather than with harsh chemical or heat treatments does not affect protein structure or cellular morphology and allows the detection of incorporated BrdUrd of morphologic or antigenic cell subsets. DNase pre-treatment may also be useful for detection of other 'hidden' DNA antigens.
|Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).|
Greipp, P R, et al.
Am. J. Hematol., 20: 289-92 (1985) 1985
Tritiated thymidine labeling indices (LI), although useful in diagnosis and prognosis of multiple myeloma, have not found wide-spread application because autoradiographic analysis is difficult and time consuming. Using a monoclonal antibody (BU-1) reactive with 5-bromo-2-deoxyuridine (BrdUrd), we have developed an immunofluorescent procedure that allows DNA S-phase measurements to be determined in 4 hr. Plasma cells are easily identified by reactivity with a fluorescein isothiocyanate-conjugated antihuman immunoglobulin, and cells in DNA S phase are detected via BU-1 and a rhodamine-conjugated antimouse immunoglobulin. Results using this method on 12 patients with multiple myeloma compare favorably (correlation coefficient 0.84), with those obtained by tritiated thymidine. This immunofluorescent slide method will facilitate application of labeling indices as a clinical test to measure disease activity in patients with multiple myeloma and other hematologic neoplasms.
|Anti-Bromodeoxyuridine, No Acid or Proteinase Required, Clone BU-1, Peroxidase Conjugated - Data Sheet|